PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.

Company profile
Ticker
PLXP
Exchange
Website
CEO
Natasha Giordano
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Dipexium Pharmaceuticals, Inc., Dipexium Pharmaceuticals, LLC
SEC CIK
Corporate docs
Subsidiaries
PLx Opco Inc. ...
PLXP stock data
News

Why Energy Stocks Traded Higher; Here Are 61 Biggest Movers From Yesterday
26 Jul 22
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday
25 Jul 22
12 Health Care Stocks Moving In Wednesday's Intraday Session
20 Jul 22
Stocks That Hit 52-Week Lows On Monday
13 Jun 22
Raymond James Maintains Outperform on PLx Pharma, Lowers Price Target to $10
16 May 22
Press releases
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update
27 Jul 22
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions
20 May 22
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update
13 May 22
Analyst ratings and price targets
Investment data
Securities sold
Number of investors
Calendar
13 May 22
8 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 52.5M | 52.5M | 52.5M | 52.5M | 52.5M | 52.5M |
Cash burn (monthly) | 5.63M | 2.66M | 6.07M | 6.43M | 5.63M | 3.73M |
Cash used (since last report) | 24.18M | 11.42M | 26.04M | 27.62M | 24.18M | 16M |
Cash remaining | 28.32M | 41.08M | 26.46M | 24.88M | 28.32M | 36.5M |
Runway (months of cash) | 5.0 | 15.4 | 4.4 | 3.9 | 5.0 | 9.8 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 22 | O'Connor Rita M | Common Stock | Buy | Acquire P | No | No | 3.6546 | 3,700 | 13.52K | 26,670 |
15 Mar 22 | O'Connor Rita M | Common Stock | Buy | Acquire P | No | No | 3.66 | 10,000 | 36.6K | 22,970 |
15 Mar 22 | Giordano Natasha | Common Stock | Buy | Acquire P | No | No | 3.6529 | 4,100 | 14.98K | 5,186 |
22 Feb 22 | Balkema Gary S. | Stock Option Common Stock | Grant | Acquire A | No | No | 4.99 | 20,000 | 99.8K | 20,000 |
22 Feb 22 | Calhoun Kirk K | Stock Option Common Stock | Grant | Acquire A | No | No | 4.99 | 20,000 | 99.8K | 20,000 |
22 Feb 22 | Casale Robert | Stock Option Common Stock | Grant | Acquire A | No | No | 4.99 | 20,000 | 99.8K | 20,000 |
Institutional ownership, Q1 2022
51.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 52 |
Opened positions | 10 |
Closed positions | 17 |
Increased positions | 11 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 133.67M |
Total shares | 14.21M |
Total puts | 156.2K |
Total calls | 149.5K |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
White Rock Capital Management | 2.81M | $22.52M |
Level One Partners | 2.77M | $22.21M |
MSD Partners | 1.88M | $7.58M |
Park West Asset Management | 1.47M | $5.95M |
Vanguard | 1.1M | $4.45M |
MS Morgan Stanley | 854.74K | $3.45M |
GW&K Investment Management | 428.17K | $1.73M |
BLK Blackrock | 406.98K | $1.64M |
Two Sigma Advisers | 393.5K | $1.59M |
Two Sigma Investments | 338.83K | $1.37M |
Financial report summary
?Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
batch, bottle, broader, capacity, category, count, Dipexium, discover, expanding, extend, flow, frozen, grocery, lining, list, longer, notwithstanding, NSAID, optimization, percentage, preclinical, proportionally, screening, seek, store, Topic, variety, warehouse
Removed:
account, accredited, affordable, agreement, allocate, annually, annum, approach, arising, arrangement, authority, bank, banking, book, borrowed, calculating, charge, Codification, commencement, compounded, computation, context, continuing, Corporation, deficit, Deposit, depreciable, dividend, employee, enacted, enactment, examination, exposure, face, feature, February, federally, fee, final, floating, foreign, franchise, fulfill, fully, gain, general, greater, housing, identified, inception, initially, institution, insured, intraperiod, investing, investment, January, July, knowledge, largest, liquid, liquidation, making, mitigate, mitigated, monthly, NDA, occurred, October, original, originally, ownership, partially, performed, placement, preference, presence, prime, qualified, qualitative, realized, reborrowed, recovered, relevant, removing, Rent, represent, requirement, requiring, resulting, review, Security, separate, settled, Silicon, simplify, simplifying, step, sublease, subsequently, supplemental, sustained, symbol, tax, taxable, temporary, thereunder, TM, unit, unpaid, Valley, York
Financial reports
Current reports
8-K
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update
13 May 22
8-K
Amendments to Articles of Incorporation or Bylaws
21 Apr 22
8-K
Regulation FD Disclosure
15 Mar 22
8-K
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
11 Mar 22
8-K
PLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update
12 Nov 21
8-K
Regulation FD Disclosure
21 Sep 21
8-K
Entry into a Material Definitive Agreement
6 Aug 21
8-K
PLx Pharma Inc. Reports Second Quarter 2021 Results and Provides Business Update
6 Aug 21
8-K
PLx Pharma Inc. Reports First Quarter 2021 Results and Provides Business Update
14 May 21
8-K
Other Events
17 Mar 21
Registration and prospectus
S-8
Registration of securities for employees
22 Nov 21
424B3
Prospectus supplement
11 Jun 21
424B3
Prospectus supplement
11 Jun 21
424B5
Prospectus supplement for primary offering
4 Mar 21
424B5
Prospectus supplement for primary offering
2 Mar 21
424B4
Prospectus supplement with pricing info
7 Jan 21
D
$18.01M in equity / options, sold $18.01M, 25 investors
30 Nov 20
S-3
Shelf registration
28 Jun 20
Other
EFFECT
Notice of effectiveness
18 Aug 21
CORRESP
Correspondence with SEC
12 Aug 21
UPLOAD
Letter from SEC
12 Aug 21
EFFECT
Notice of effectiveness
7 Jan 21
CORRESP
Correspondence with SEC
3 Jan 21
UPLOAD
Letter from SEC
27 Dec 20
EFFECT
Notice of effectiveness
9 Jul 20
CORRESP
Correspondence with SEC
5 Jul 20
UPLOAD
Letter from SEC
1 Jul 20
CT ORDER
Confidential treatment order
19 Sep 19
Ownership
4
PLx Pharma / Natasha Giordano ownership change
16 Mar 22
4
PLx Pharma / Rita M O'Connor ownership change
16 Mar 22
4
PLx Pharma / Michael J Valentino ownership change
24 Feb 22
4
PLx Pharma / Rita M O'Connor ownership change
24 Feb 22
4
PLx Pharma / JOHN HADDEN ownership change
24 Feb 22
4
PLx Pharma / Natasha Giordano ownership change
24 Feb 22
4
PLx Pharma / Robert Casale ownership change
24 Feb 22
4
PLx Pharma / KIRK K CALHOUN ownership change
24 Feb 22
4
PLx Pharma / Gary S. Balkema ownership change
24 Feb 22
SC 13G/A
PLx Pharma / WHITE ROCK CAPITAL MANAGEMENT ownership change
16 Feb 22
Patents
Utility
PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME
2 Jun 22
Disclosed herein are novel drug carriers including a non-aqueous pH dependent release system and a non-aqueous pH dependent reassembly/assembly and reabsorption/absorption system.
Utility
PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND METHODS FOR MAKING AND USING SAME
6 Jan 22
Disclosed herein are novel drug carriers including a non-aqueous pH dependent release system and a non-aqueous pH dependent reassembly/assembly and reabsorption/absorption system.
Utility
PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
28 Sep 20
Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts.
Utility
pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
15 Jul 20
Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts.
Utility
PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
11 May 20
Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts.
Transcripts
2022 Q1
Earnings call transcript
13 May 22
2021 Q4
Earnings call transcript
11 Mar 22
2021 Q3
Earnings call transcript
12 Nov 21
2021 Q2
Earnings call transcript
7 Aug 21
2021 Q1
Earnings call transcript
14 May 21
2020 Q4
Earnings call transcript
12 Mar 21
2020 Q3
Earnings call transcript
16 Nov 20
2020 Q2
Earnings call transcript
14 Aug 20
2020 Q1
Earnings call transcript
15 May 20
2019 Q4
Earnings call transcript
13 Mar 20
Reddit threads
Daily Discussion Thread - May 13th, 2022
13 May 22
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - March 11th, 2022
11 Mar 22
Daily Discussion Thread - March 10th, 2022
10 Mar 22
Daily Discussion Thread - March 9th, 2022
9 Mar 22
Daily Discussion Thread - March 8th, 2022
8 Mar 22
(ACXP) Acurx Pharmaceuticals full DD
7 Dec 21
(11/12) Friday's Pre-Market Stock Movers & News
12 Nov 21
(11/12) Friday's Pre-Market Stock Movers & News
12 Nov 21
Daily Discussion Thread - November 12th, 2021
12 Nov 21